Humanigen Stock Jumps As Lenzilumab Application Is Under Review In UK For COVID-19

by Vandana Singh, Benzinga Editor

July 9, 2021 10:29 AM | 1 min read | Make a Comment

The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted for review Humanigen Inc's HGEN marketing application seeking approval for lenzilumab in COVID-19.
MHRA has accepted the application under expedited COVID-related rolling review, with assessment expected to occur more rapidly than a standard rolling review.
Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF).
GM-CSF is an upstream regulator of many inflammatory cytokines and chemokines involved in the cytokine storm.
Price Action: HGEN shares are up 1.68% at $16.93 during the market session on the last check Friday.

Posted In: Biotech News Health Care Small Cap FDA General Briefs Covid-19

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.